Clinical Evaluation of Injectable Lorazepam as a Premedicant

Cd, Blitt; Wc, Petty; Wa, Wright; Wright, Brittany T.

doi:10.1213/00000539-197607000-00014

Anesthesia & Analgesia

1976

DOI: 10.1213/00000539-197607000-00014

|View full text |Cite

Clinical Evaluation of Injectable Lorazepam as a Premedicant

Blitt Cd¹,

Petty Wc²,

Wright Wa³

et al.

Abstract: A double-blind comparison of lorazepam and placebo, lorazepam and pentobarbital, and a comparison of lorazepam IV drip versus lorazepam IV bolus as a premedicant showed this new agent to offer promise as a sedative premedicant. However, the potency of the drug demands caution, and its use for outpatient premedication is not recommended.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1977

1982

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 7 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results

Greenblatt

Comer

Elliott

et al. 1977

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Four healthy male volunteers received 5 mg lorazepam as a single intravenous injection. Concentrations of lorazepam and its glucuronide metabolite were determined in multiple venous blood samples drawn during the 48 hours after dosing and in all urine collected during 96 hours after the dose. Mean pharmacokinetic parameters for lorazepam were: apparent elimination half-life, 13.2 hours; volume of distribution, 0.84 liter/kg; total clearance, 55.3 ml/min. Lorazepam glucuronide, the major metabolic product of lorazepam, promptly appeared in blood, reached peak levels within 6 hours of the dose, then declined in parallel with the parent compound. A mean of 69 per cent of the dose was recovered in urine as lorazepam glucuronide.

show abstract

Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results

Greenblatt

Comer

Elliott

et al. 1977

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

Diazepam and Lorazepam for Intravenous Surgical Premedication

Conner

Katz

Bellville

et al. 1978

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Diazepam, 10 and 20 mg, and 2 and 4 mg lorazepam were studied as intravenous surgical premedicants in 120 patients. Relief of anxiety, sedation, patient acceptance, lack of recall, and side effects were the variables evaluated. Both diazepam and lorazepam proved to be excellent surgical premedicants. The basic difference between the two drugs is temporal. Both medications produce similar relief of anxiety, sedation, patient acceptance, and lack of recall. The clinical effects of intravenous diazepam peaks in 2 to 3 minutes and diminishes thereafter. Intravenous lorazepam has a latent period of 8 to 15 minutes, with increasing effects at 15 to 30 minutes.

show abstract

Lorazepam and diazepam as adjuncts to epidural anaesthesia for caesarean section

Ong

Pickering

Palahniuk

et al. 1982

Canad. Anaesth. Soc. J.

View full text Add to dashboard Cite

Lorazepam 0.05 mg-kg -1 and diazepam 0.1 mg-kg -t administered intravenously were compared as sedatives for 42 patients undergoing Caesarean Section under epidural anaesthesia. After receivin~ the drug, 15 per cent of the diazepam patients and 32 per cent of the lorazepam patients were still agitated. Ten per cent of the diazepam patients and 36 per cent of the lorazepam patients had severe symptoms of delirium. These included hallucinations, confusion, agitation, restlcssness, inappropriate weeping and repetitive hand movements.Memory impairment was greater with lorazepam. Thirty-five per cent of the diazepam patients had pain at the injection site. None of the lorazepam patients had such pain. Respiratory rate, heart rate and mean blood pressure did not change significantly in either group. Half the patients who had been given lorazepam had side effects that were bothersome enough to cause them to complain the following day. Lorazepam and diazepam were both unsatisfactory as sedatives for patients having Caesarean Section.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical Evaluation of Injectable Lorazepam as a Premedicant

Cited by 7 publications

References 0 publications

Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results

Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results

Diazepam and Lorazepam for Intravenous Surgical Premedication

Lorazepam and diazepam as adjuncts to epidural anaesthesia for caesarean section

Contact Info

Product

Resources

About